Okabe, S., Tauchi, T., Tanaka, Y., Kitahara, T., Kimura, S., Maekawa, T., & Ohyashiki, K. (2014). Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. Landes Bioscience.

Okabe, Seiichi, Tetsuzo Tauchi, Yuko Tanaka, Toshihiko Kitahara, Shinya Kimura, Taira Maekawa, e Kazuma Ohyashiki. Efficacy of the Dual PI3K and MTOR Inhibitor NVP-BEZ235 in Combination With Nilotinib against BCR-ABL-positive Leukemia Cells Involves the ABL Kinase Domain Mutation. Landes Bioscience, 2014.

Okabe, Seiichi, et al. Efficacy of the Dual PI3K and MTOR Inhibitor NVP-BEZ235 in Combination With Nilotinib against BCR-ABL-positive Leukemia Cells Involves the ABL Kinase Domain Mutation. Landes Bioscience, 2014.